D. Feldman

发表

Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients

Donavan T. Cheng, Alexander V Penson, Benjamin E. Gross, 2017, Nature Medicine.

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

R. Frisina, N. Cox, E. Gamazon, 2016, Clinical Cancer Research.

Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.

D. Feldman, M. Barchi, F. Cavallo, 2013, The International journal of developmental biology.

Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition

R. Chaganti, G. Bosl, D. Feldman, 2012, PloS one.

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

M. Lacouture, D. Feldman, Y. Balagula, 2012, Investigational New Drugs.

The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study

D. Feldman, S. Williams, A. Budnick, 2020, Cancer.

High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.

D. Feldman, E. Riedel, G. Soff, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Chad A. LaGrange, David C. Smith, W. Lowrance, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

S. Fosså, H. Sesso, D. Feldman, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term response to sunitinib therapy for metastatic renal cell carcinoma.

R. Motzer, R. Motzer, J. Hsieh, 2013, Clinical genitourinary cancer.

Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma

R. Motzer, M. Ginsberg, D. Feldman, 2008 .

Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.

R. Frisina, S. Fosså, M. Dolan, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural immunity to pluripotency antigen OCT4 in humans

M. Dhodapkar, D. Feldman, H. Zebroski, 2010, Proceedings of the National Academy of Sciences.

RAS/MAPK Pathway Driver Alterations Are Significantly Associated with Oncogenic KIT Mutations in Germ-cell Tumors.

Chad M. Vanderbilt, M. Ladanyi, V. Reuter, 2020, Urology.

Interrogation of a Context‐Specific Transcription Factor Network Identifies Novel Regulators of Pluripotency

Mariano J. Alvarez, A. Viale, A. Califano, 2015, Stem cells.

Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy.

R. Motzer, D. Bajorin, B. Carver, 2015, Urology.

Clinical features, presentation, and tolerance of platinum‐based chemotherapy in germ cell tumor patients 50 years of age and older

R. Motzer, M. Voss, G. Bosl, 2013, Cancer.

Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer.

C. Gross, Jersey Chen, D. Feldman, 2016, The Journal of urology.

Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.

R. Motzer, G. Bosl, D. Feldman, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms

R. Frisina, E. Gamazon, S. Fosså, 2019, Clinical Cancer Research.

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

N. Hanna, D. Feldman, L. Einhorn, 2022, Investigational New Drugs.

Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease

L. Schwartz, P. Russo, V. Reuter, 2011, American journal of clinical oncology.

Integrated Molecular Characterization of Testicular Germ Cell Tumors

Joshua M. Stuart, Jeffrey A Jones, David I Heiman, 2018, Cell reports.

Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience.

R. Motzer, B. Carver, G. Bosl, 2016, Urology.

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

R. Motzer, M. Voss, G. Iyer, 2021, Clinical Genitourinary Cancer.

Hearing Loss in Adult Survivors of Childhood Cancer Treated with Radiotherapy

D. Feldman, K. Oeffinger, A. Budnick, 2018, Children.

The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach.

G. Bosl, D. Feldman, S. Funt, 2016, Oncology.

Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing.

A. Lenis, M. Ladanyi, K. Offit, 2021, European urology oncology.

Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors After Cisplatin-Based Chemotherapy

H. Vargas, H. Sesso, D. Feldman, 2022, JNCI cancer spectrum.

Microwave Ablation (MWA) for the Treatment of a Solitary, Chemorefractory Testicular Cancer Liver Metastasis

S. Solomon, E. Petre, J. Erinjeri, 2015, CardioVascular and Interventional Radiology.

Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy

R. Frisina, R. Huddart, D. Feldman, 2021, Cancer medicine.

COMPARATIVE GENOMIC PROFILING OF MATCHED PRIMARY AND METASTATIC TUMORS IN RENAL CELL CARCINOMA: MP39‐02

C. Bourque, N. Socci, R. Motzer, 2017, European urology focus.

Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer

R. Frisina, M. Dolan, D. Feldman, 2022, Cancer medicine.

Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis.

R. Motzer, M. Voss, V. Hatzoglou, 2015, Clinical genitourinary cancer.

Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.

M. Berger, R. Motzer, V. Reuter, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

N. Hanna, D. Feldman, L. Einhorn, 2022, Investigational New Drugs.

Late Relapse of Testicular Germ Cell Tumors.

B. Carver, D. Feldman, J. Sheinfeld, 2015, The Urologic clinics of North America.

A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.

R. Motzer, M. Voss, G. Bosl, 2011, Hematology/oncology clinics of North America.

Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

S. Sleijfer, G. Bosl, D. Feldman, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach.

R. Motzer, E. Plimack, D. Feldman, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization.

D. Feldman, 2010, Oncology.

Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.

M. Ladanyi, M. Berger, R. Motzer, 2022, JCO precision oncology.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Donavan T. Cheng, Alexander V Penson, Benjamin E. Gross, 2017, Nature Medicine.

Reply to L.C. Pagliaro et al.

D. Feldman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

R. Motzer, D. Sjoberg, D. Bajorin, 2015, Urology.

Clinical Outcome of Patients with Fibrosis/Necrosis at Post‐Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors

R. Motzer, D. Bajorin, B. Carver, 2015, The Journal of urology.

Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors

David R. Jones, V. Rusch, M. Bains, 2020, Annals of surgery.

State-of-the-Art Management of Germ Cell Tumors.

D. Feldman, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.

R. Motzer, D. Bajorin, B. Carver, 2019, Urology.

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

W. Lowrance, N. Hanna, T. Powles, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are Some Cases of Somatic Type Malignancy Potentially Avoidable?

D. Feldman, J. Sheinfeld, Maria F. Becerra, 2016, The Journal of urology.

Good-risk-advanced germ cell tumors: historical perspective and current standards of care

R. Motzer, D. Feldman, 2009, World Journal of Urology.

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

R. Motzer, J. Hsieh, Chung-Han Lee, 2016, The oncologist.

Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting

D. Berney, H. Samaratunga, J. Srigley, 2018, Histopathology.

Reply to L.H. Einhorn et al

M. Bains, R. Motzer, G. Bosl, 2010 .

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.

R. Motzer, D. Sjoberg, D. Bajorin, 2018, Urology.

Rare de novo germline copy-number variation in testicular cancer.

B. Yamrom, J. Kendall, A. Leotta, 2012, American journal of human genetics.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

R. Motzer, D. Feldman, R. Robbins, 2007, Journal of the National Cancer Institute.

High-dose chemotherapy and stem cell transplantation for advanced testicular cancer

R. Motzer, M. Voss, D. Feldman, 2011, Expert review of anticancer therapy.

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis.

D. Feldman, M. Carlo, 2016, European urology.

Progression‐free and overall survival in patients with relapsed/refractory germ cell tumors treated with single‐agent chemotherapy: Endpoints for clinical trial design

R. Motzer, D. Bajorin, G. Bosl, 2012, Cancer.

Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC).

R. Motzer, M. Ginsberg, D. Feldman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma.

R. Motzer, G. V. Kondagunta, M. Ginsberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

R. Huddart, T. Powles, C. Bokemeyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes of local and metastatic testicular sex cord-stromal tumors.

V. Reuter, R. Motzer, H. Al-Ahmadie, 2013, The Journal of urology.

Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.

D. Solit, D. Feldman, J. Sheinfeld, 2022, The Journal of molecular diagnostics : JMD.

The conundrum of clinical trials in adult germ-cell tumours.

D. Feldman, C. Kollmannsberger, T. Powles, 2013, The Lancet. Oncology.

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.

R. Motzer, M. Voss, Chung-Han Lee, 2022, European urology.

Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes.

R. Motzer, P. Russo, A. Hakimi, 2019, Clinical genitourinary cancer.

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

L. Collette, S. Culine, R. Huddart, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors.

N. Hanna, D. Feldman, L. Einhorn, 2020 .

Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors

D. Feldman, D. McHugh, 2018, Advances in urology.

Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.

R. Motzer, D. Kraus, D. Bajorin, 2010, Urology.

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report

G. Iyer, D. Bajorin, M. Lacouture, 2021, Case Reports in Oncology.

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors

R. Motzer, M. Lacouture, D. Feldman, 2012, Cancer.

Epidemiology, Biology, and Genetics of Adult Male Germ Cell Tumors

R. Chaganti, D. Feldman, Darren R. Feldman, 2015 .

Testicular cancer

D. Berney, P. Albers, Liang Cheng, 2018, Nature Reviews Disease Primers.

Fertility preservation strategies for male patients with cancer

D. Feldman, J. Mulhall, T. Kolon, 2013, Nature Reviews Urology.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

V. Vacic, N. Schultz, M. Berger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update in germ cell tumours

D. Feldman, 2015, Current opinion in oncology.

Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors

V. Reuter, G. Iyer, H. Al-Ahmadie, 2014, Clinical Cancer Research.

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

R. Motzer, M. Voss, E. Reznik, 2021, Molecular Cancer Research.

Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death.

P. Russo, D. Feldman, B. Konety, 2014, Urologic oncology.

Commentary Testicular Cancer Survivorship: Research Strategies and Recommendations

P. Okunieff, S. Fosså, L. Constine, 2022 .

Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.

E. Bass, B. Leibovich, P. Pierorazio, 2019, The Journal of urology.

Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.

D. Feldman, L. Einhorn, C. Albany, 2018, The oncologist.

Medical treatment of advanced testicular cancer.

R. Motzer, G. Bosl, D. Feldman, 2008, JAMA.

Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways

D. Feldman, M. Jasin, M. Barchi, 2021, Cancers.

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

David R. Jones, N. Schultz, M. Ladanyi, 2021, Cell.

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

T. Choueiri, M. Michaelson, T. Olencki, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.

Li-Xuan Qin, Victor E Reuter, A. Olshen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.

R. Motzer, V. Reuter, S. Tickoo, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

L. Collette, R. Huddart, C. Bokemeyer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor.

B. Taylor, C. Iacobuzio-Donahue, V. Reuter, 2020, The Journal of clinical investigation.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

E. Gamazon, S. Fosså, M. Dolan, 2017, Clinical Cancer Research.

TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.

M. Bains, R. Motzer, D. Bajorin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

R. Motzer, J. Chaim, A. Hakimi, 2020, Journal for immunotherapy of cancer.

Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.

R. Motzer, P. Russo, A. Hakimi, 2019, Clinical genitourinary cancer.

Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.

R. Motzer, P. Russo, J. Hsieh, 2017, Urologic oncology.

Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

R. Motzer, P. Russo, V. Reuter, 2017, European urology focus.

Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.

R. Motzer, P. Russo, A. Hakimi, 2017, Urologic oncology.

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

M. Ladanyi, A. Hakimi, R. Motzer, 2017, Kidney cancer.

Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.

R. Motzer, P. Russo, A. Hakimi, 2016, European urology focus.

Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.

H. Kume, Y. Homma, R. Motzer, 2016, European urology focus.

The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.

M. Lacouture, D. Feldman, B. Garden, 2012, European journal of cancer.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

R. Motzer, C. Karlo, A. Hakimi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

V. Reuter, R. Motzer, S. Tickoo, 2012, Investigational New Drugs.

Novel targets and therapies for metastatic renal cell carcinoma.

R. Motzer, D. Feldman, 2006, Oncology.

Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma

M. Ladanyi, K. Offit, R. Motzer, 2018, JAMA oncology.

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

R. Motzer, M. Ginsberg, D. Feldman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

R. Motzer, M. Voss, E. Reznik, 2021 .

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

R. Motzer, V. Reuter, J. Chaim, 2020, Cancer.

Oncologist use and perception of large panel next-generation tumor sequencing

D. M. Hyman, J. Galle, N. Schultz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs.

C. Bourque, B. Taylor, A. Viale, 2020, JCO precision oncology.

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

R. Motzer, M. Voss, E. Reznik, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma

R. Motzer, P. Russo, A. Hakimi, 2021, Clinical Cancer Research.

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

R. Motzer, O. Akin, M. Voss, 2020, BMC Urology.

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors

R. Motzer, V. Reuter, D. Bajorin, 2021, The oncologist.

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Nancy J Cox, Robert D Frisina, M Eileen Dolan, 2014, Journal of the National Cancer Institute.

Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors

M. Dolan, D. Feldman, L. Einhorn, 2020, Clinical Cancer Research.

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

S. Fosså, H. Sesso, S. Lipshultz, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late cardiovascular toxicity following chemotherapy for germ cell tumors.

D. Feldman, R. Steingart, Wendy L. Schaffer, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes

R. Motzer, J. Chaim, A. Hakimi, 2017, Clinical genitourinary cancer.

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Julie L. Yang, N. Socci, V. Seshan, 2021, Genome medicine.

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

T. Choueiri, M. Michaelson, T. Olencki, 2018, European journal of cancer.

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Mellar P. Davis, E. Raymond, D. Feldman, 2011, The oncologist.

Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy

Frederick G. Strathmann, S. Fosså, M. Dolan, 2019, Clinical Cancer Research.

Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors

N. Hanna, D. Feldman, S. Perkins, 2021, Investigational new drugs.

Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors.

D. Feldman, L. Einhorn, L. Garbo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves

E. Robilotti, M. Kamboj, M. Perales, 2021, Transplantation and Cellular Therapy.

Reply to B.I. Rini et al

R. Motzer, D. Feldman, F. Scappaticci, 2010 .

Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study

S. Fosså, R. Huddart, K. Kroenke, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial

R. Huddart, T. Powles, D. Feldman, 2011, Journal of Cancer.

Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.

R. Motzer, B. Carver, G. Bosl, 2012, Urology.

Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.

R. Motzer, D. Bajorin, B. Carver, 2006, Urology.

The role of high-dose chemotherapy in the management of germ cell tumors

D. Feldman, D. Bastos, 2014, Current opinion in oncology.

Salvage high-dose chemotherapy for germ cell tumors.

T. Powles, D. Feldman, 2015, Urologic oncology.

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

T. Choueiri, M. Michaelson, M. Morris, 2019, The oncologist.

Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma

L. Schwartz, P. Russo, R. Motzer, 2008 .

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

R. Motzer, G. Bosl, M. Ginsberg, 2010, Investigational New Drugs.

Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors

R. Frisina, S. Fosså, R. Huddart, 2020, JNCI cancer spectrum.

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.

S. Fosså, M. Dolan, R. Huddart, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

S. Fosså, R. Huddart, H. Sesso, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

R. Motzer, M. Voss, M. Ginsberg, 2012, Cancer.

Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets.

M. Ladanyi, Jianjiong Gao, R. Motzer, 2019, JCO precision oncology.

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

M. Bains, R. Motzer, D. Bajorin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors

S. Fosså, D. Feldman, P. Monahan, 2020, JNCI cancer spectrum.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin‐based Chemotherapy: Application of the Framingham Risk Score

R. Frisina, S. Fosså, M. Dolan, 2018, Clinical genitourinary cancer.

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Frazier, R. Huddart, T. Powles, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.

R. Motzer, V. Reuter, D. Bajorin, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Ronald C. Chen, T. Choueiri, M. Morris, 2020, Cancer.

Patterns of relapse and second malignancy after adjuvant external beam radiation therapy for stage I-II seminoma.

M. Zelefsky, M. Folkert, D. Feldman, 2017 .

Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.

M. Bains, R. Motzer, D. Bajorin, 2015, Clinical genitourinary cancer.

Paclitaxel, Ifosfamide and Cisplatin (TIP) Beyond Its Original Indication for Salvage Treatment of Germ Cell Tumors

M. Voss, D. Feldman, 2011, Oncology Research and Treatment.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

E. V. Van Allen, S. Signoretti, R. Motzer, 2018, Cancer Immunology Research.

Development of a risk stratification system to guide treatment for female germ cell tumors.

G. Bosl, D. Feldman, C. Aghajanian, 2015, Gynecologic oncology.

Thoracic Metastasectomy in Germ Cell Tumor Patients Treated with First-Line Versus Salvage.

David R. Jones, M. Bains, V. Reuter, 2020, The Annals of thoracic surgery.

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach

A. Olshen, V. Reuter, J. Korkola, 2015, PloS one.

Personalized Medicine and Imaging Presence of Somatic Mutations within PIK 3 CA , AKT , RAS , and FGFR 3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors

V. Reuter, G. Iyer, H. Al-Ahmadie, 2014 .

Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.

D. Chi, D. Feldman, C. Aghajanian, 2023, Gynecologic oncology.

Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.

R. Motzer, D. Bajorin, B. Carver, 2015, The Journal of urology.

Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.

P. Russo, O. Akin, R. Motzer, 2022, European Urology.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

Chad A. LaGrange, David C. Smith, W. Lowrance, 2019 .

Treatment options for stage I nonseminoma.

D. Feldman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Redefining the IGCCCG classification in advanced non-seminoma

L. Collette, R. Huddart, D. Feldman, 2019, Annals of Oncology.

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

R. Motzer, V. Reuter, B. Costello, 2018 .

Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study.

D. Feldman, C. Nelson, M. Hoyt, 2023, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments

R. Frisina, S. Fosså, R. Huddart, 2022, Ear and hearing.

Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy

R. Frisina, S. Fosså, H. Sesso, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

T. Choueiri, M. Michaelson, T. Olencki, 2018, European journal of cancer.

Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection.

V. Reuter, R. Motzer, R. Thompson, 2012, Urology.

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

M. Gonen, M. Shah, G. Schwartz, 2009, Clinical Cancer Research.

Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors

R. Motzer, G. V. Kondagunta, G. Bosl, 2007, Investigational New Drugs.

Evaluation of lymph node counts in primary retroperitoneal lymph node dissection

V. Reuter, R. Motzer, D. Bajorin, 2010, Cancer.

566 EVALUATION OF LYMPH NODE COUNTS IN PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION

V. Reuter, R. Motzer, R. Thompson, 2010 .

Contemporary lymph node counts during primary retroperitoneal lymph node dissection.

V. Reuter, R. Motzer, R. Thompson, 2011, Urology.

Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).

R. Motzer, T. Choueiri, D. Feldman, 2017 .

Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum.

G. Bosl, D. Feldman, J. Sheinfeld, 2019, European urology.

Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.

L. Collette, R. Huddart, D. Feldman, 2020 .

Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)

R. Motzer, G. V. Kondagunta, M. Ginsberg, 2007 .

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Donavan T. Cheng, Benjamin E. Gross, Michael H. Eubank, 2017, Nature Network Boston.

Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events.

M. Berger, R. Motzer, C. Karlo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

J. Hajdenberg, R. Motzer, D. Feldman, 2013, Investigational New Drugs.

Testicular cancer survivorship: research strategies and recommendations.

P. Okunieff, S. Fosså, L. Constine, 2010, Journal of the National Cancer Institute.

Clinical features, presentation, and tolerance of platinum‐based chemotherapy in germ cell tumor patients 50 years of age and older

R. Motzer, M. Voss, G. Bosl, 2013, Cancer.

Testicular cancer

D. Berney, P. Albers, Liang Cheng, 2018, Nature Reviews Disease Primers.

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

M. Gonen, M. Shah, G. Schwartz, 2009, Clinical Cancer Research.

Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).

R. Motzer, J. Chaim, A. Hakimi, 2019, Journal of Clinical Oncology.

Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.

C. Bourque, N. Socci, R. Motzer, 2017, European urology focus.

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.

J. Chaim, R. Motzer, M. Voss, 2023, European Urology Oncology.

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

R. Motzer, D. Sjoberg, D. Bajorin, 2015, Urology.

Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors

R. Motzer, D. Bajorin, D. Feldman, 2023, Cancer.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

S. Fosså, R. Huddart, H. Sesso, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of high-dose chemotherapy in the management of germ cell tumors

D. Feldman, D. Bastos, 2014, Current opinion in oncology.

Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS).

S. Fosså, H. Sesso, D. Feldman, 2017 .

Clinical, sociodemographic, and behavioral factors associated with cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study.

S. Fosså, R. Huddart, H. Sesso, 2017 .

Overcoming barriers to tumor genomic profiling through direct-to-patient outreach.

N. Socci, A. Viale, M. Ladanyi, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in Wolfram syndrome 1 (WFS1) gene.

R. Frisina, E. Gamazon, M. Dolan, 2016 .